(NASDAQ: MAZE) Maze Therapeutics's forecast annual revenue growth rate of -33.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.57%.
Maze Therapeutics's revenue in 2026 is $20,000,000.On average, 13 Wall Street analysts forecast MAZE's revenue for 2026 to be $1,241,947,657, with the lowest MAZE revenue forecast at $1,084,767,116, and the highest MAZE revenue forecast at $2,324,500,962. On average, 13 Wall Street analysts forecast MAZE's revenue for 2027 to be $499,324,945, with the lowest MAZE revenue forecast at $0, and the highest MAZE revenue forecast at $3,486,751,443.
In 2028, MAZE is forecast to generate $468,054,872 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $2,905,626,203.